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Introduction
It was demonstrated the wide potential for biomedical
applications of nanoscale gold particles because of their
unique biological properties [1,2]. The use of gold nano-
particles in cardiology is promising to develop funda-
mentally new methods of diagnosis and treatment.
Aims and objectives
The aim was to test effects of nanoparticles using sug-
gested congestive heart failure rat model, applying intra-
pleural and intraveonous injection, to compare with
proved medication Simdax; to test gold nanoparticle for
drug delivery, to test sonoporation effect to increase
nanoparticles delivery into myocardial cell in rats.
Material and methods
Wistar rats weighing 180-200 g (n=54) of each sex were
selected on the basis of analogies for experiment, within
two weeks received intravenous injection of doxorubicin
Sigma in cumulative dose of 12.0 mg / kg to model
advance heart failure, registered by ultrasonography
using ultrasound transducers up to 12 MHz. At 14th day
we formed 6 groups with 8 rats in each: first three
groups of animals received simdax, nanoparticles and
gold conjugate (simdax, nanogold) into pleural cavities
in a dose of 0.06 ml per animal. 7th (n=8) group was
control (saline). The fourth, fifth and sixth groups of
animals received simdax, gold nanoparticles and conju-
gate intravenously in same dose. We considered hydro-
thorax as most representative sign for effective dynamic
assessment of heart failure regression. Sonoporation of
gold nanoparticles to cardiomyocytes was tested.
Results
In all animals of 6 groups after 3rd day after medication
injection no ascites, no liver enlargement was registered
(compare to controls p<0.001). The linear cranio-caudal
measurements of fluid level pleural cvities were as fol-
lowed: for gold nanoparticles intrapleural right 1.8 ±0.11
mm; left – 2.1±0.13 mm, compared to hydrothorax in
controls right 6 ±0.46 mm; left 7 ±0.35 mm. Conjugate
injection shown significantly higher hydrothorax reduc-
tion than injection of Simdax only (p<0.01); gold nano-
particles injection shown significantly higher than
injection of Simdax (P<0.05) gold nanoparticles and
conjugate shown non significant difference in rat recov-
ery. Difference in rat life continuity was significant
between simdax vs. nanogold P < 0.05) and simdax vs
conjugate (P < 0.05). Sonoporation enhances AuNPs
transfer into cell and mytochondrias that were
highly localized, and was superior to controls (P <0.01
for both).
Conclusions
Gold nanoparticles conjugated with cardiotropic drugs
have significant cardioprotective effects for doxorubicin
induced heart failure rats, higher than Simdax only.
Gold nanoparticle alone show effects similar to the con-
jugate injection. Intrapleural (local delivery) route is pre-
ferred over intravenous (systemic) according to all tested
parameters. Sonoporation is able to enhance gold nano-
particle delivery to myocardial cells in vivo.
Outlook and expert recommendations
It is recommended to create international project to study
gold nanoparticles for development nanoconstructions to
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treat patients with heart failure. Extend studies to nano-
particles application for neurodegenerative, heart, liver,
kidney diseases, muscle dystrophy, combining with biolo-
gical therapies to archive sustainable effects from thera-
nostic approach.
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